Summary

The human respiratory tract harbours a complex and dynamic assembly of microorganisms—bacteria, fungi and viruses—that collectively influence respiratory physiology, immunity and disease susceptibility. Once thought to be sterile, both the upper and lower airways are now recognised as distinct ecological niches populated by transient and resident microbes. Community composition varies along the airway, shaped by mechanisms such as mucociliary clearance, cough reflex and local immune surveillance. In health, a balanced microbiome contributes to barrier function, immune calibration and resistance to pathogen overgrowth. Perturbations—termed dysbiosis—have been linked to a spectrum of respiratory disorders including asthma, chronic obstructive pulmonary disease, bronchiectasis, pneumonia and post-viral sequelae. Advances in culture-independent sequencing and integrative metagenomic analyses have enabled longitudinal monitoring of these microbial networks and their interactions with host factors. Emerging evidence highlights cross-talk between the respiratory and gut microbiomes, and the influence of non-bacterial components (the virome and mycobiome) on inflammatory pathways. Understanding the temporal evolution of these communities offers new avenues for diagnostics, risk stratification and microbiota-targeted therapies in respiratory medicine.

Research from Nature Portfolio

A comprehensive longitudinal study in critically ill patients with acute respiratory failure has tracked microbial changes across the oral cavity, lungs and gut. Using high-resolution 16S and ITS amplicon sequencing alongside Nanopore metagenomics, researchers documented a progressive decline in microbial diversity and loss of beneficial anaerobes in all three compartments during mechanical ventilation. Concomitant rises in opportunistic pathogens correlated with clinical factors such as chronic obstructive pulmonary disease, immunosuppression and antibiotic exposure. Unsupervised clustering of lung microbiota profiles emerged as an independent predictor of patient survival, outperforming conventional clinical scores and host-response biomarkers. Validation in COVID-19 cohorts underlined the prognostic potential of lung microbial signatures. These findings open the door to precision microbiota-guided interventions in critical care.

Microbiome Dynamics in Respiratory Health publication trend

The graph below shows the total number of articles in microbiome dynamics in respiratory health across all publications each year (not limited to Nature Index journals).

Technical terms

Microbiome: The collective genome and community of microorganisms inhabiting a particular environment.

Dysbiosis: An imbalance or maladaptation in microbial community structure associated with disease.

Metagenomics: Culture-independent analysis of genetic material recovered from environmental samples.

Bronchoalveolar lavage: A procedure in which fluid is introduced and retrieved from the lower respiratory tract for microbial or cellular analysis.

Host–microbiota interactions: Bidirectional physiological and biochemical crosstalk between a host organism and its resident microbes.

References

  1. Longitudinal multicompartment characterization of host-microbiota interactions in patients with acute respiratory failure. Nature Communications (2024).
  2. Lung microbiome: new insights into the pathogenesis of respiratory diseases. Signal Transduction and Targeted Therapy (2024).
  3. The microbiome of the upper respiratory tract in health and disease. BMC Biology (2019).

About these summaries

This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.

Nature Index 2026 Regenerative medicine

Regenerative medicine has the potential to transform the treatment of chronic and life-threatening diseases. But major challenges remain, such as overcoming immune rejection and ensuring that new therapies are developed using more inclusive data sets. In this supplement, we explore the discoveries that are driving the field, the barriers that could limit its progress, and the teams and institutions that are making their mark.

Nature Index 2026 Regenerative medicine
Access for free
Nature Strategy Reports
Turn complex research questions into confident strategic decisions 

When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.

  • Benchmark your performance against global peers using robust, methodologically sound analysis.

  • Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.

  • Gain tailored, decision-ready recommendations aligned to your strategic priorities.

Talk to us to learn more about our data dashboards and bespoke strategy reports.

Nature Masterclasses
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.

Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:

  • Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.

  • Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.

  • Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.

Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.